AYUSH Sector Receives Unprecedented Boost in Union Budget 2026-27, Gains European Market Access Through India EU FTA
In a landmark development for India’s traditional and alternative medicine systems, the Union Budget for 2026-27 has delivered a substantial financial and strategic thrust to the AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy) sector. This push, coupled with the recent Free Trade Agreement (FTA) with the European Union, signifies a transformative moment. The government is orchestrating a dual strategy: fortifying the domestic ecosystem of AYUSH through massive institutional and infrastructural investment while simultaneously unlocking lucrative international markets, particularly in Europe. This concerted effort aims to reposition AYUSH from a niche, traditional practice into a globally competitive, standardized, and scientifically aligned pillar of India’s healthcare and economic architecture.
Budgetary Infusion: Building a World-Class AYUSH Infrastructure
Finance Minister Nirmala Sitharaman’s budget proposals for 2026-27 mark a decisive shift in the state’s approach to AYUSH. The total allocation has soared to ₹4,408 crore, a significant jump from ₹3,992 crore in the previous fiscal (2025-26) and more than double the ₹2,122 crore allocated in 2020-21. This financial commitment underscores a long-term vision beyond mere symbolic support.
The most ambitious announcement is the plan to establish three new All-India Institutes of Ayurveda (AIIA), explicitly designed to be the “gold standard” for traditional medicine, mirroring the role of AIIMS in allopathy. These institutes are envisioned as holistic centers of excellence that will integrate patient care, high-level research, and postgraduate education. Their AIIMS-like model suggests an intent to create apex institutions that can drive evidence-based protocols, attract top talent, and lend unparalleled credibility to the sector.
Simultaneously, the budget pledges funds to upgrade the WHO Global Traditional Medicine Centre in Jamnagar. This move is strategically geopolitical; it positions India as the undisputed global leader in setting norms, standards, and documentation protocols for traditional medicine worldwide. By hosting and enhancing this WHO center, India aims to dictate the terms of global engagement with traditional healing systems, a soft power play with significant economic and cultural ramifications.
At the grassroots level, the National AYUSH Mission (NAM) has received a massive 66% increase in funding, raising its budget to ₹1,300 crore. This mission is the workhorse for integration and modernization. The funds are earmarked for modernizing local AYUSH hospitals and dispensaries, a critical step in improving patient experience and outcomes. A key component is the “co-location” policy—placing AYUSH clinics within existing primary health centers, community health centers, and modern medicine district hospitals. This fosters a more integrated healthcare model, giving patients choice under one roof and potentially easing the burden on overstretched allopathic facilities. The upgrade of existing centers to focus on preventive health aligns perfectly with the core strengths of systems like Ayurveda and Yoga, which emphasize wellness and disease prevention.
Recognizing that quality control is paramount for domestic trust and export success, the budget also allocates resources to upgrade AYUSH pharmacies and drug-testing laboratories. This addresses long-standing concerns about standardization and contamination. In a innovative blend of tradition and technology, the government announced Bharat-VISTAAR, a multilingual AI assistant designed to support farmers cultivating medicinal plants. It will provide real-time advice on cultivation practices for better quality, current market prices, and guidance on export certification—directly linking agricultural livelihoods to the AYUSH value chain.
The European Gateway: How the India-EU FTA Unlocks Markets
The budgetary push finds a powerful external complement in the newly minted India-European Union Free Trade Agreement. Historically, AYUSH practitioners and products faced formidable barriers in Europe. Indian Ayurvedic degrees were often not recognized, and practitioners could not offer services. Companies faced regulatory uncertainty and non-tariff barriers.
The FTA dismantles several of these obstacles:
-
Practitioner Mobility: In EU countries that do not have specific regulations governing traditional medicine (like many in Eastern Europe), Indian AYUSH practitioners can now provide services based on qualifications obtained in India. This opens doors for wellness tourism and the establishment of Indian-run clinics.
-
Investment Security: Indian companies receive a legal guarantee to open wellness centers, Ayurvedic clinics, and spas across the EU’s 27 member states. This protects them from sudden, adverse changes in local laws, providing the stability needed for long-term investment.
-
Mutual Recognition of Standards: India and the EU will work towards mutual recognition of laboratory test results and safety certifications. This is a game-changer for exports. An Ayurvedic supplement tested and certified in an accredited Indian lab will likely be accepted by European customs, drastically reducing costs and delays.
-
Protection of Traditional Knowledge: The FTA formally recognizes India’s Traditional Knowledge Digital Library (TKDL), a vast database of traditional formulations. This provides a legal shield against “biopiracy” or wrongful patent claims by foreign entities on India’s ancient medicinal knowledge.
This FTA effectively creates a structured pathway for AYUSH as a service and product to enter a high-value, regulated market, transforming it from an ethnic offering to a mainstream global wellness alternative.
Institutional Backbone: The AYUSH Ecosystem
The budgetary allocations and FTA benefits are building upon an already extensive institutional framework. The AYUSH sector boasts a network of dedicated hospitals, prestigious institutes, and regulatory bodies.
The crown jewels are the ‘Institutes of National Importance’, such as the existing All-India Institute of Ayurveda in New Delhi and the National Institute of Homoeopathy in Kolkata. These are complemented by specialized institutions for Siddha, Unani, Yoga, and Naturopathy. Research is spearheaded by councils like the Central Council for Research in Ayurvedic Sciences (CCRAS). Education standards are overseen by the National Commission for Indian System of Medicine (NCISM) and the National Commission for Homoeopathy (NCH), which aim to ensure affordable and reliable medical education. Drug quality is the mandate of the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H), which sets official standards. The National Medicinal Plants Board (NMPB), with its state-level counterparts, works to ensure a sustainable supply chain of high-quality raw materials. Schemes like ‘AYURGYAN’ (promoting education) and ‘Ayurswasthay Yojana’ (community health) round out the holistic policy approach.
The Scientific and Ethical Debate: Scrutiny Amidst Growth
The aggressive promotion of AYUSH is not without intense controversy. Critics, led by the Indian Medical Association (IMA), challenge the scientific underpinnings of many traditional practices. They argue that unlike allopathic drugs, which must undergo rigorous Randomized Controlled Trials (RCTs) for safety and efficacy, many AYUSH treatments are based on ancient texts and observational history, lacking verifiable empirical evidence. Safety concerns, particularly regarding the presence of heavy metals like lead and mercury in certain classical formulations, have led to health advisories in countries like Australia, the U.S., and New Zealand.
The most contentious issue is “mixopathy”—the state-sanctioned blurring of lines between traditional and modern medicine. In 2020, the Central Council of Indian Medicine authorized postgraduate Ayurveda students to train in 58 surgical procedures. The IMA decried this as “legalised quackery,” arguing that surgery requires comprehensive training in anatomy, physiology, anaesthesia, and modern diagnostics, which AYUSH curricula do not adequately provide. This controversy exploded in 2025 when the Andhra Pradesh government allowed Ayurveda practitioners to perform such surgeries independently, sparking nationwide protests and a legal battle now pending before the Supreme Court.
Further friction exists over AYUSH practitioners prescribing allopathic medicines like antibiotics and steroids in some states, a practice allowed via executive orders to address rural doctor shortages. The mainstream medical community warns this risks irrational drug use and exacerbates the global crisis of antimicrobial resistance.
Implications: From Welfare to Global Industry
The confluence of massive funding and international market access is set to catalyze a fundamental transformation. Independent estimates project the AYUSH sector to be worth $26.5 billion (approx. ₹2.3 lakh crore) by 2026, with startups and MSMEs comprising 80% of this vibrant ecosystem. The government’s vision is clear: to evolve AYUSH from a domestic, welfare-adjacent component of public health into a regulated, export-oriented industry and a significant source of economic growth and employment.
The new AIIAs and upgraded testing facilities represent an attempt to recast traditional medicine as being science-based rather than solely lineage-based. This drive for standardization and quality is essential for global market success.
However, this very integration into global markets brings with it a double-edged sword. While standardization may open doors abroad, it will inevitably raise expectations for evidence, accountability, and transparency at home. The global scrutiny on quality, proof of efficacy, and clear demarcation of practice boundaries will subject the AYUSH sector to a level of institutional discipline and regulatory oversight that it has historically not fully faced. In this sense, the government’s powerful push may ultimately force the sector to reconcile its traditional roots with the rigorous demands of 21st-century global healthcare, a challenging but necessary evolution for its long-term sustainability and credibility.
Conclusion
The 2026-27 Budget and the India-EU FTA together represent a watershed moment for AYUSH. They provide the capital, the institutional heft, and the international pathway to scale dramatically. The ambition is to create a parallel, globally respected healthcare and wellness pillar that is distinctly Indian. Yet, this journey will be closely watched. The sector stands at a crossroads where it must embrace scientific validation and clear ethical boundaries to match its economic and geopolitical promise. Its success will depend not just on investment and trade deals, but on its ability to navigate the complex interplay between tradition and modernity, and to earn the trust of both domestic patients and international consumers through demonstrable safety and efficacy.
Q&A:
Q1: What are the three key pillars of the Union Budget 2026-27’s push for the AYUSH sector?
A1: The budget focuses on three main pillars: 1) Building Elite Institutions: Establishing three new All-India Institutes of Ayurveda (modeled on AIIMS) and upgrading the WHO Global Traditional Medicine Centre in Jamnagar to set global standards. 2) Strengthening Grassroots Infrastructure: A 66% hike in the National AYUSH Mission budget to modernize local facilities, co-locate AYUSH clinics in existing hospitals, and promote preventive health. 3) Ensuring Quality & Supply Chain: Upgrading pharmacies and drug-testing labs, and launching the AI tool Bharat-VISTAAR to support medicinal plant farmers with cultivation and export advice.
Q2: How does the India-EU Free Trade Agreement specifically address past barriers faced by AYUSH in Europe?
A2: The FTA addresses four major past barriers: a) Practitioner Recognition: Allows Indian AYUSH practitioners to offer services in EU countries without specific traditional medicine regulations, based on Indian qualifications. b) Investment Security: Provides a legal guarantee for Indian companies to open wellness centers/clinics in the EU, protecting them from arbitrary law changes. c) Trade Facilitation: Aims for mutual recognition of lab tests and safety certifications, easing the import of Indian AYUSH products. d) Knowledge Protection: Recognizes India’s Traditional Knowledge Digital Library (TKDL) to prevent biopiracy of traditional formulations.
Q3: What is “mixopathy” and why is it a major point of controversy?
A3: “Mixopathy” refers to the government-sanctioned blurring of boundaries between traditional (AYUSH) and modern medical practice. The core controversy erupted when the Central Council of Indian Medicine allowed postgraduate Ayurveda students to train in 58 surgical procedures. The Indian Medical Association (IMA) and modern medicine practitioners argue that surgery requires extensive, dedicated training in modern anatomy, anaesthesia, and perioperative care, which AYUSH curricula do not provide. They view this as “legalised quackery” that compromises patient safety. The issue reached a flashpoint in 2025 with state-level permissions for independent Ayurvedic surgeries, leading to Supreme Court challenges.
Q4: Name four key autonomous bodies or institutes under the AYUSH sector and their primary roles.
A4: Key bodies include: 1) National Commission for Indian System of Medicine (NCISM): Regulates education and ensures standards for Ayurveda, Siddha, Unani, and Sowa-Rigpa. 2) Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H): Sets the official standards and quality specifications for all AYUSH drugs. 3) Central Council for Research in Ayurvedic Sciences (CCRAS): The premier body for formulating and coordinating scientific research in Ayurveda. 4) National Medicinal Plants Board (NMPB): Promotes the cultivation, conservation, and sustainable management of medicinal plants across the country.
Q5: What are the two primary challenges related to evidence and safety that the AYUSH sector faces as it expands globally?
A5: The two major challenges are: 1) Evidence-Based Scrutiny: Global markets, especially regulated ones like the EU, demand rigorous empirical evidence (like Randomized Controlled Trials) for safety and efficacy—a standard many AYUSH treatments, based on textual or observational history, have not yet universally met. 2) Safety and Standardization Concerns: Instances of heavy metal (e.g., lead, mercury) contamination in some classical Ayurvedic products have led to international health advisories. As the sector scales, ensuring consistent, contaminant-free manufacturing and standardized, verifiable formulations is critical to maintaining trust and meeting international regulatory requirements.
